OPKO Health, Inc. Investor Relations INVESTORS Latest News BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant Emerges in The U.S. Nov 29, 2021 VIEW ALL NEWS Latest Financial Results Q3 2021 Quarter Ended Sep 30, 2021 Earnings Release PDF HTML AUDIO Earnings Webcast 10-Q Filing PDF HTML XBRL ZIP XLS HTML Latest Annual Filing Fiscal Year Ended Dec 31, 2020 VIEW FILING Email Alerts Stay informed and receive company updates straight to your inbox. SIGN UP TODAY Stock Information Corporate Presentation DOWNLOAD CORPORATE PRESENTATION Company Overview OPKO Health, Inc. is a diversified healthcare company that seeks to serve unmet patient needs and establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, one of the nation's largest clinical laboratories, with a core genetic testing business and a 300 person sales and marketing team to drive growth and leverage new products, including 4KScore® prostate cancer laboratory developed test and the Claros® 1 point-of-care device, which is capable of in office measurement of PSA within 10 minutes. Our pharmaceutical business features Rayaldee® (calcifediol), an FDA approved treatment for SHPT in stage 3-4 chronic kidney disease (CKD) patients with vitamin D insufficiency, which was launched in November 2016. Besides nephrology, we have strategic focus on the development of diagnostic and therapeutic agents in urology and endocrinology. Pipelines using the same proprietary platforms, such as the long acting CTP, Reverse-PEGylation, and the Claros® 1 immunoassay system are in various stage of discovery, lead molecule validation, early clinical, clinical, and expanded post marketing indications. We invest in development of low risk proven therapeutic targets and utilize validated technology to expand our diagnostic test menu for unmet medical needs. We have production and distribution assets abroad, several strategic investments, and an active business development strategy. We expect our future growth to arise from leveraging our proprietary technology, development strengths, and the pursuit of complementary acquisitions and investments. Leadership Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success. VIEW MANAGEMENT TEAM VIEW BOARD OF DIRECTORS Investor Contact Information Company OPKO Health, Inc. 4400 Biscayne Boulevard Miami, FL 33137 T: 305-575-4100 contact@opko.com Investor Relations LHA Yvonne K. Briggs T: 310-691-7100 YBriggs@lhai.com LHA Bruce Voss T: 310-691-7100 bvoss@lhai.com Transfer Agent American Stock Transfer & Trust Company, LLC 6201 15th Avenue Brooklyn, NY 11209 T: 718-921-8317 www.amstock.com Email Alerts Tear Sheet Contacts RSS News Feed © 2021 OPKO Health, Inc. All Rights Reserved. PRIVACY POLICY GOVERNANCE TERMS OF USE SITEMAP Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.